MXPA04003742A - Farmaco conteniendo 3-(3-dimetilamino-1-etil-2-metil-propil)fenol con liberacion lenta de la sustancia activa. - Google Patents

Farmaco conteniendo 3-(3-dimetilamino-1-etil-2-metil-propil)fenol con liberacion lenta de la sustancia activa.

Info

Publication number
MXPA04003742A
MXPA04003742A MXPA04003742A MXPA04003742A MXPA04003742A MX PA04003742 A MXPA04003742 A MX PA04003742A MX PA04003742 A MXPA04003742 A MX PA04003742A MX PA04003742 A MXPA04003742 A MX PA04003742A MX PA04003742 A MXPA04003742 A MX PA04003742A
Authority
MX
Mexico
Prior art keywords
dimethylamino
phenol
propyl
ethyl
methyl
Prior art date
Application number
MXPA04003742A
Other languages
English (en)
Spanish (es)
Inventor
Bartholom Us Johannes
Original Assignee
Gr Nenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26010444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04003742(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10152469A external-priority patent/DE10152469A1/de
Priority claimed from DE2002148309 external-priority patent/DE10248309A1/de
Application filed by Gr Nenthal Gmbh filed Critical Gr Nenthal Gmbh
Publication of MXPA04003742A publication Critical patent/MXPA04003742A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MXPA04003742A 2001-10-24 2002-10-22 Farmaco conteniendo 3-(3-dimetilamino-1-etil-2-metil-propil)fenol con liberacion lenta de la sustancia activa. MXPA04003742A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10152469A DE10152469A1 (de) 2001-10-24 2001-10-24 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
DE2002148309 DE10248309A1 (de) 2002-10-16 2002-10-16 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung
PCT/EP2002/011809 WO2003035053A1 (de) 2001-10-24 2002-10-22 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
MXPA04003742A true MXPA04003742A (es) 2004-07-23

Family

ID=26010444

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003742A MXPA04003742A (es) 2001-10-24 2002-10-22 Farmaco conteniendo 3-(3-dimetilamino-1-etil-2-metil-propil)fenol con liberacion lenta de la sustancia activa.

Country Status (28)

Country Link
US (7) US20050058706A1 (https=)
EP (1) EP1439829B1 (https=)
JP (2) JP4758064B2 (https=)
KR (1) KR100958045B1 (https=)
CN (1) CN100402021C (https=)
AR (1) AR036943A1 (https=)
AT (1) ATE303802T1 (https=)
AU (1) AU2002349001C1 (https=)
BR (1) BRPI0213653B8 (https=)
CA (1) CA2464578C (https=)
CO (1) CO5570662A2 (https=)
CY (1) CY2012022I2 (https=)
DE (1) DE50204198D1 (https=)
DK (1) DK1439829T3 (https=)
EC (1) ECSP045102A (https=)
ES (1) ES2248622T3 (https=)
HU (1) HU230161B1 (https=)
IL (2) IL161587A0 (https=)
MX (1) MXPA04003742A (https=)
MY (1) MY127797A (https=)
NO (2) NO331896B1 (https=)
NZ (1) NZ532999A (https=)
PE (1) PE20030527A1 (https=)
PL (1) PL216535B1 (https=)
PT (1) PT1439829E (https=)
SI (1) SI1439829T1 (https=)
WO (2) WO2003035053A1 (https=)
ZA (1) ZA200403928B (https=)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
PT1562567T (pt) 2002-11-22 2017-08-24 Gruenenthal Gmbh Combinação de analgésicos selecionados e inibidores da cox-ii
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
NZ545202A (en) * 2003-08-06 2010-03-26 Gruenenthal Chemie Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide
DE602004007905T2 (de) * 2004-06-28 2008-05-08 Grünenthal GmbH Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
BRPI0513300B1 (pt) * 2004-07-01 2018-11-06 Gruenenthal Gmbh forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2- metil-lpropil)-fenol
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
RU2442576C2 (ru) * 2006-04-28 2012-02-20 Грюненталь Гмбх Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
CN105561311B (zh) * 2006-04-28 2019-07-16 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
CN101091725A (zh) * 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
DE102007019417A1 (de) 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
CN102908339A (zh) * 2007-11-23 2013-02-06 格吕伦塔尔有限公司 他喷他多组合物
WO2009071310A1 (de) * 2007-12-07 2009-06-11 Grünenthal GmbH Kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
BRPI0921725A2 (pt) 2008-10-30 2016-01-05 Grüenthal GmbH formas de dosagem potentes do tapentadol
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
TWI473628B (zh) 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
US9579285B2 (en) * 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
JP5905872B2 (ja) * 2010-04-07 2016-04-20 ルピン・リミテッド タペンタドールの制御放出医薬組成物
EP2566461A2 (de) * 2010-05-05 2013-03-13 Ratiopharm GmbH Festes tapentadol in nicht-kristalliner form
SI2582366T1 (sl) * 2010-06-15 2016-02-29 Gruenenthal Gmbh Farmacevtska kombinacija za zdravljenje bolečine
PL2588093T3 (pl) 2010-06-30 2017-07-31 Grünenthal GmbH Tapentadol do zastosowania w leczeniu zespołu jelita drażliwego
EP3597628A1 (en) 2010-07-23 2020-01-22 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
CA2828635C (en) 2011-03-04 2020-01-14 Grunenthal Gmbh Parenteral administration of tapentadol
KR101946790B1 (ko) 2011-03-04 2019-02-13 그뤼넨탈 게엠베하 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
RS56692B1 (sr) 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol
US20120309840A1 (en) 2011-04-05 2012-12-06 Gruenenthal Gmbh Treatment of Pain Associated with Trigeminal Neuralgia
RS58064B1 (sr) 2011-04-05 2019-02-28 Gruenenthal Gmbh Tapentadol za sprečavanje hronifikacije bola
LT3272343T (lt) 2011-04-29 2020-05-11 Grünenthal GmbH Tapentadolis, skirtas depresijos ir nerimo prevencijai ir gydymui
EP2736501B1 (en) * 2011-07-29 2017-12-20 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
EP2606879A1 (en) 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP2942054A1 (en) * 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
EP3273953B1 (en) 2015-03-27 2019-01-02 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
CN109996533A (zh) 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
US20180369151A1 (en) * 2017-05-29 2018-12-27 Grünenthal GmbH Multiparticulate oral dosage form providing prolonged release of tapentadol
PE20230105A1 (es) 2020-03-02 2023-01-25 Gruenenthal Chemie Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol
EP3875079A1 (en) 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
PL3875077T3 (pl) * 2020-03-02 2024-03-11 Grünenthal GmbH Postać dawkowania zapewniająca przedłużone uwalnianie soli kwasu fosforowego tapentadolu
ES3060121T3 (en) * 2020-03-02 2026-03-25 Gruenenthal Gmbh Dosage form providing prolonged release of tapentadol phosphoric acid salt
AU2020100442B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
ES3010208T3 (en) * 2020-03-16 2025-04-01 Gruenenthal Gmbh Scored tablet comprising tapentadol
DE202020104285U1 (de) 2020-07-24 2020-12-18 Grünenthal GmbH Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure
HUE059465T2 (hu) * 2020-11-10 2022-11-28 Gruenenthal Gmbh A tapentadol L-(+)- borkõsav-só késleltetett felszabadulású adagolási formája
PE20240113A1 (es) 2020-11-10 2024-01-22 Gruenenthal Chemie Formas de dosificacion de liberacion sostenida de una sal de tapentadol con acido l-(+)-tartarico
DE202020005470U1 (de) 2020-11-10 2022-01-25 Grünenthal GmbH Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
DE2117239A1 (de) 1971-04-08 1972-11-16 König, Wilhelm, 4712 Werne Verfahren zum Erstellen von Wänden aus Schalungssteinen
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5641631A (en) 1983-01-10 1997-06-24 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
GB8519310D0 (en) 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
JP3140465B2 (ja) * 1992-09-18 2001-03-05 山之内製薬株式会社 ハイドロゲル徐放性製剤
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
CA2149408C (en) 1993-11-17 2008-04-01 Kinuko Oku Compositions for curing affected abnormal tissues, method for the preparation thereof, and usage thereof
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
CN1125572A (zh) * 1994-12-28 1996-07-03 顺德市广容制药厂 一种罗通定痛释片的制作方法
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
DE19525137C2 (de) 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
DE19609847A1 (de) 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
IL123505A (en) * 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
CA2290624C (en) * 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
DE19901683B4 (de) 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
AU764453B2 (en) * 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10248309A1 (de) 2002-10-16 2004-04-29 Grünenthal GmbH 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung

Also Published As

Publication number Publication date
CY2012022I1 (el) 2015-08-05
WO2003035053A1 (de) 2003-05-01
ZA200403928B (en) 2005-07-27
US20170087103A1 (en) 2017-03-30
ES2248622T3 (es) 2006-03-16
US20180221308A1 (en) 2018-08-09
SI1439829T1 (sl) 2006-02-28
HK1068539A1 (en) 2005-04-29
MY127797A (en) 2006-12-29
NO20041924L (no) 2004-05-11
CN100402021C (zh) 2008-07-16
HUP0402104A2 (hu) 2005-03-29
CO5570662A2 (es) 2005-10-31
US20160151309A1 (en) 2016-06-02
US20050058706A1 (en) 2005-03-17
KR100958045B1 (ko) 2010-05-17
CA2464578C (en) 2011-10-11
HU230161B1 (en) 2015-09-28
EP1439829A1 (de) 2004-07-28
ATE303802T1 (de) 2005-09-15
BRPI0213653B1 (pt) 2018-04-03
US20130237608A1 (en) 2013-09-12
BR0213653A (pt) 2004-10-26
AU2002349001B2 (en) 2003-05-06
PL369756A1 (en) 2005-05-02
DE50204198D1 (de) 2005-10-13
CN1607947A (zh) 2005-04-20
AR036943A1 (es) 2004-10-13
CA2464578A1 (en) 2003-05-01
EP1439829B1 (de) 2005-09-07
NO2012007I1 (no) 2012-05-21
NO331896B1 (no) 2012-04-30
NZ532999A (en) 2007-06-29
IL161587A (en) 2009-12-24
ECSP045102A (es) 2004-06-28
NO2012007I2 (no) 2013-01-02
US11007156B2 (en) 2021-05-18
PL216535B1 (pl) 2014-04-30
CY2012022I2 (el) 2015-08-05
JP2005506367A (ja) 2005-03-03
JP4758064B2 (ja) 2011-08-24
PT1439829E (pt) 2005-11-30
WO2003035054A1 (de) 2003-05-01
AU2002349001C1 (en) 2022-04-14
US20200038344A1 (en) 2020-02-06
PE20030527A1 (es) 2003-07-26
US20120034304A1 (en) 2012-02-09
KR20040047964A (ko) 2004-06-05
JP2010280697A (ja) 2010-12-16
BRPI0213653B8 (pt) 2021-05-25
DK1439829T3 (da) 2005-10-10
IL161587A0 (en) 2004-09-27

Similar Documents

Publication Publication Date Title
MXPA04003742A (es) Farmaco conteniendo 3-(3-dimetilamino-1-etil-2-metil-propil)fenol con liberacion lenta de la sustancia activa.
IL111647A (en) Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation
CA2232310A1 (en) Stable compositions containing n-propargyl-1-aminoindan
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
EP2322146A3 (en) Microcapsule formulations comprising two pharmaceutically active ingredients
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
DE60124294D1 (de) Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe
BR9810320A (pt) Composição farmacêutica sólida, contendo derivados de benzofurano
EP2266542A3 (en) Controlled release nanoparticulate compositions
ES2331046T1 (es) Formulacion de liberacion controlada.
WO2001078725A3 (en) Modified release formulations containing a hypnotic agent
BR0212475A (pt) Composições farmacêuticas
BR0307893A (pt) Formulação oftálmica com sistema de goma
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
BR0007360A (pt) Composição de liberação controlada
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
EA200001201A3 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
BR0317567A (pt) Composição farmacêutica de liberação controlada de tamsulosina e processo para sua preparação
GEP20053447B (en) Antibiotic Preparation with Retarding Active Ingredient Release
WO2005009329A3 (de) 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
AU2697100A (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
CA2397942A1 (en) Controlled release pharmaceutical composition containing tramadol hydrochloride and method for its preparation
WO2006107593A3 (en) Matrix-based pulse release pharmaceutical formulation
DE60319983D1 (de) Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan

Legal Events

Date Code Title Description
FG Grant or registration